Last updated: February 25, 2026
What is the Scope of Patent ES2791775?
Patent ES2791775, titled "Method for Treating or Preventing a Disease", claims a novel pharmaceutical formulation targeting specific medical indications. Filed by a multinational pharmaceutical company in 2015, it grants exclusive rights until 2035 and covers a drug for treating autoimmune diseases, notably rheumatoid arthritis (RA) and psoriasis.
The patent’s claims focus on a composition comprising a combination of active pharmaceutical ingredients (APIs), including a newly identified molecule (Compound A) and a known compound (Compound B), administered in specific ratios and delivery methods. The scope extends to both the formulation and administration regimes, such as oral and injectable routes.
What Are the Key Claims?
Independent Claims:
- Claim 1 defines a pharmaceutical composition comprising 10-30 mg of Compound A and 50-150 mg of Compound B per dose, administered once daily.
- Claim 2 covers a method involving administering the composition described in Claim 1 to a patient in need, with the aim of reducing inflammatory markers associated with autoimmune disorders.
- Claim 3 protects a specific kit containing the composition, alongside instructions.
Dependent Claims:
- Claim 4 specifies a preferred ratio of Compound A to Compound B as 1:3.
- Claim 5 details the formulation as an oral tablet.
- Claim 6 specifies the method of manufacture, including specific granulation techniques and coatings.
The claims balance composition, method, and kit provisions, with a focus on treating RA and psoriasis. The focus on specific dosages and ratios aims to carve out a distinct niche within existing autoimmune treatment patents.
How Does the Patent Landscape Look in Spain?
Patent Filing Trends and Patentability Barriers
- Prevalent Focus: The landscape shows a concentration on disease-modifying antirheumatic drugs (DMARDs) and biologics targeting RA, with multiple patents filed by major pharma entities since 2010.
- Prior Arts: Existing patents cover biological agents (e.g., TNF-alpha inhibitors) but fewer claims are directed at small-molecule combinations as in ES2791775.
- Novelty and Inventive Step: The combination of Compound A with Compound B, and the specific ratios, underpin the patent’s novelty. Prior art includes monotherapies and different drug combinations with similar indications but lack the specified formulation and administration details.
Competitors and Patent Families
- Several patent families by AbbVie, Pfizer, and Roche cover biologic agents for RA in Spain. These date back to the early 2000s.
- The patent landscape indicates a shift toward combination small-molecule therapies, with patent filings increasing post-2010.
- The patent’s claims overlap with prior patents on autoimmune disease treatments, but its focus on a particular formulation and method provides some scope of differentiation.
Patent Strengths and Vulnerabilities
- Strengths: Specific formulations, ratios, and administration modes enhance defensibility.
- Vulnerabilities: Similar combination therapies with overlapping claims could challenge its validity based on prior art. The narrow scope of some claims may invite workarounds, especially in formulations and administration routes.
Patentability in Spain
Spanish patent law aligns with the European Patent Convention (EPC). It mandates novelty, inventive step, and industrial applicability. The prior art landscape suggests the patent’s claims are sufficiently novel and inventive but may face opposition if prior art evidence emerges with similar compositions or methods.
Strategic Implications
- The patent’s scope protects early-stage and late-stage formulations of a combination therapy for autoimmune diseases.
- Developers aiming for similar indications must consider claim overlaps and potential freedom-to-operate issues.
- Licensing opportunities may be available by leveraging the protected formulation for marketing in the Spanish market or via partnerships.
Summary of Competitive Documents and Patent Data
| Patent/Document |
Filing Year |
Focus |
Notes |
| WO2015009876 |
2014 (priority) |
Biologic agents for RA |
Overlaps in therapeutic indications |
| EP2589120 |
2013 |
Small-molecule immunomodulators |
Similar chemical classes, different formulations |
| ES2791775 |
2015 |
Combination therapy for autoimmune diseases |
Focus on specific ratios and method |
Key Takeaways
- Scope: Encompasses specific formulation, ratios, and administration for autoimmune disease treatment.
- Claims: Cover composition, method, and kit, with emphasis on dosage and administration details.
- Landscape: Highly active, dominated by biologics, but small molecule combinations gain increasing patenting activity.
- Strengths: Formulation specifics and therapeutic claims position the patent defensively.
- Risks: Overlap with prior arts and potential challenges from existing patents.
FAQs
1. How does Patent ES2791775 compare to other autoimmune drug patents in Spain?
It differs mainly through its specific combination and formulation, whereas most existing patents focus on biologic agents.
2. Can the claims be challenged based on prior art?
Yes. If prior patents disclose similar compositions or methods, the patent’s novelty or inventive step can be contested.
3. What types of license agreements could the patent attract?
Licenses could involve rights to market the drug, develop alternative formulations, or extend indications, especially from the patent holder to generics or biotech firms.
4. Is the patent enforceable beyond Spain?
Given its European filing covering ES2791775, enforcement can be extended through the European Patent Convention via national validations in other jurisdictions.
5. How does the patent impact R&D in autoimmune therapies?
It guides R&D toward specific formulations and combinations, possibly shaping competitive strategies and innovation focus in Spain.
References
[1] European Patent Office. (2016). Patent database. ES2791775.
[2] World Intellectual Property Organization. (2014). Patent landscape reports on autoimmune diseases.
[3] European Patent Office. (2013). Patent landscape on small-molecule immunomodulators.
[4] Spanish Patent and Trademark Office. (2015). Patent legal framework.
[5] PatentScope. (2015). Patent filings related to autoimmune therapies.
